Q1 2026 SAB Biotherapeutics Inc Earnings Call Transcript
Key Points
- SAB Biotherapeutics Inc (SABS) has advanced its lead product candidate, SAB142, into a registrational Phase IIb trial called SAFEGUARD, with enrollment progressing on schedule.
- The company received written confirmation from the FDA that C-peptide may serve as a surrogate endpoint for accelerated approval, de-risking their regulatory path.
- SAB142's Phase I data showed promising results, including beta cell preservation and a favorable safety profile, with no serum sickness and low immunogenicity.
- SAB Biotherapeutics Inc (SABS) has a strong cash position of $217.6 million, providing an operational runway through 2028.
- A multi-year agreement with Emergent BioSolutions has been executed to support the process development and manufacturing of SAB142, positioning the company for potential commercial launch.
- The company reported a net loss of $18.9 million for the first quarter of 2026, compared to $5.2 million for the same period in 2025.
- R&D expenses increased significantly to $13.4 million in Q1 2026 from $7.7 million in Q1 2025, driven by ongoing investments in the SAB142 program.
- G&A expenses also rose to $6.6 million in Q1 2026 from $3.1 million in Q1 2025, primarily due to higher non-cash stock-based compensation and personnel-related costs.
- Other income decreased to $1.1 million in Q1 2026 from $5.6 million in Q1 2025, driven by changes in the fair value of warrant liabilities.
- The company has not disclosed specific plans for releasing Part A data of the SAFEGUARD trial ahead of Part B, which may limit transparency for stakeholders.
Good morning and welcome to the SAB Biotherapeutics Inc conference call to discuss First Quarter 2026 financial results and business updates.
Listeners are invited to review the full text of the forward-looking statements from the morning's quarterly earnings press release.
Company management may provide projections during the call, and actual results could differ materially due to several factors, including those outlined in the company's latest filings with the SEC.
Currently, all participants are in a listen-only mode.
Following management's remarks, we will open the call for questions. This call is being webcast live and can be accessed on the Investor section of SAB Bio's website at SAB Biotherapeutics, where a replay will be available.
I'll now turn the call over to Samuel Reich, Chief Executive Officer of SAB Bio.
Thank you, operator. Good morning, and thank you to everyone joining us for our first earnings call.
We are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
